Kathy High recently joined AskBio (Asklepios BioPharmaceutical, Inc.) as president after a long and successful career in gene therapy research. Jason Mast of Endpoints News discusses her impressive career and why taking a break made her more successful. Kathy High also reveals her thoughts on the future of gene therapy.
“It had been six frenzied years since she co-founded Spark Therapeutics, 15 since she first pitched her Children’s Hospital of Philadelphia colleague Jean Bennett on starting a trial for what would eventually become the first approved gene therapy in the United States. When Roche finally closed their $4.3 billion buyout of Spark last February, High quietly exited for a sabbatical at Rockefeller University in Manhattan.” Read more here.
(Source: Jason Mast, Endpoints News, 2/4/21)